Last edition
News about "LEO Pharma"
LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.
LEO Pharma | 19/08/2026 | By News Bureau
Gilead and LEO Pharma to Advance Development of Oral STAT6 Program
STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others.
LEO Pharma | 13/01/2025 | By Aishwarya | 299
Nathalie Daste brings extensive experience in organization design, transformation and capability building in the healthcare sector.
LEO Pharma | 29/08/2023 | By Manvi | 968
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
LEO Pharma | 22/08/2023 | By Sudeep Soparkar | 1022
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy